Analysis reveals outcomes of hematopoietic stem cell transplantation in immunity disorders, suggesting targeted therapies enhance decision-making.
Previous experience implies that younger age and fewer co-morbidities at time of HSCT improve outcomes, but limited natural history data combined with increased use of targeted therapies make HSCT decisions difficult in new diseases. Adoption of disease-appropriate scoring tools may aid decision making.
No takes yet. Share an insight, caveat, or question.
Laberko et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: